Natasja Nielsen Viller

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

Penka S. Petrova, Natasja Nielsen Viller, Mark Wong et al. · Clinical Cancer Research · 2016 · 276 citations

Life Sciences, Immunology, Oncology +17

Targeting CD47 in Sézary syndrome with SIRPαFc

Lisa D. Johnson, Swati Banerjee, Oleg Kruglov et al. · Blood Advances · 2019 · 98 citations · Full text

Medicine, Immunology, Oncology +16

TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma

Daisuke Ennishi, Shannon Healy, Ali Bashashati et al. · Nature Medicine · 2020 · 80 citations · Full text

Medicine, Genetics, Oncology +13

TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets

Gloria H. Y. Lin, Vien Chai, Vivian Lee et al. · PLoS ONE · 2017 · 62 citations · Full text

Life Sciences, Immunology, Oncology +17

Interleukin‐15‐activated natural killer cells kill autologous osteoclasts via <scp>LFA</scp>‐1, <scp>DNAM</scp>‐1 and <scp>TRAIL</scp>, and inhibit osteoclast‐mediated bone erosion <i>in vitro</i>

Shan Feng, S.H. Madsen, Natasja Nielsen Viller et al. · Immunology · 2015 · 47 citations · Full text

Life Sciences, Cell Biology, Immunology +16